GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jeil Pharma Holdings Inc (XKRX:002620) » Definitions » Selling, General, & Admin. Expense

Jeil Pharma Holdings (XKRX:002620) Selling, General, & Admin. Expense : ₩82,562 Mil (TTM As of Mar. 2024)


View and export this data going back to 1988. Start your Free Trial

What is Jeil Pharma Holdings Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Jeil Pharma Holdings's selling, general, & admin. expense for the three months ended in Mar. 2024 was ₩21,919 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was ₩82,562 Mil.


Jeil Pharma Holdings Selling, General, & Admin. Expense Historical Data

The historical data trend for Jeil Pharma Holdings's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jeil Pharma Holdings Selling, General, & Admin. Expense Chart

Jeil Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 79,734.18 83,068.09 86,328.30 79,432.78 80,545.79

Jeil Pharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19,903.37 19,934.84 19,767.28 20,940.30 21,919.50

Competitive Comparison of Jeil Pharma Holdings's Selling, General, & Admin. Expense

For the Drug Manufacturers - Specialty & Generic subindustry, Jeil Pharma Holdings's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jeil Pharma Holdings's Selling, General, & Admin. Expense Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jeil Pharma Holdings's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Jeil Pharma Holdings's Selling, General, & Admin. Expense falls into.



Jeil Pharma Holdings Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩82,562 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jeil Pharma Holdings  (XKRX:002620) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Jeil Pharma Holdings Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Jeil Pharma Holdings's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Jeil Pharma Holdings (XKRX:002620) Business Description

Traded in Other Exchanges
N/A
Address
745-5, Banpo-dong, Seocho-gu, Seoul, KOR, 137-810
Jeil Pharma Holdings Inc is involved in manufacture and distribution of pharmaceutical products. The company mainly produces finished pharmaceutical products and active pharmaceutical ingredients. It has categorized its products in Antibiotic, Oncology, Cardiovascular, Gastrointestinal, Urology, Respiratory etc. The firm's manufacturing facility and research and development institute located at Yongin-si, Gyeonggi-do in Korea.

Jeil Pharma Holdings (XKRX:002620) Headlines

No Headlines